# US 2016/0354426 A1 · Methods of diagnosing and treating asthma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354426 A1
- Document ID: US20160354426A1
- Status: Published application
- Kind: A1
- Application number: 15/235,310
- Filed: 2016-08-12
- Published: 2016-12-08
- Earliest claimed: 2006-11-03
- Assignees: Alba Therapeutics Corporation
- Applicants: Alba Therapeutics Corporation
- Inventors: Blake Paterson
- Web page: https://patentgrep.com/patent/US20160354426A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist.

## Claims

### Claim 1

A method of diagnosing asthma in a subject, comprising:
obtaining a sample from the subject; and
determining zonulin in the sample, wherein the presence of zonulin is predictive of asthma.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the sample is a bronchoalveolar lavage (BAL) sample.

### Claim 3 (depends on 1)

A method according to claim 1, further comprising determining one or more chemokines in the sample.

### Claim 4 (depends on 3)

A method according to claim 3, wherein at least one of the chemokines is selected from the group consisting of TARC, MDC, and IP-10.

### Claim 5 (depends on 1)

A method according to claim 1, wherein determining zonulin concentration comprises:
contacting the sample with a first antibody that binds to zonulin under binding conditions;
contacting the bound sample with a second antibody that binds zonulin under binding conditions; and
detecting the presence of bound second antibody.

### Claim 6 (depends on 5)

A method according to claim 5, wherein at least one antibody was raised against a protein comprising a fragment of zonula occludens toxin.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the first antibody was raised against a protein comprising a fragment of zonula occludens toxin.

### Claim 8 (depends on 6)

A method according to claim 6, wherein the first antibody was raised against a protein comprising AG fragment of zonula occludens toxin.

### Claim 9 (depends on 6)

A method according to claim 6, wherein at least one antibody was raised against a protein comprising zonula occludens toxin.

### Claim 10 (depends on 6)

A method according to claim 6, wherein the second antibody was raised against a protein comprising zonula occludens toxin.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the second antibody comprises a detectable moiety.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the detectable moiety comprises biotin.

### Claim 13

A kit for diagnosing asthma, comprising:
means for detecting zonulin; and
means for detecting at least one cytokine

### Claim 14 (depends on 13)

A kit according to claim 13, wherein the means for detecting zonulin comprises:
a first container containing a first antibody and a second container containing a second antibody.

### Claim 15 (depends on 13)

A kit according to claim 13, further comprising a container containing AG fragment of zonula occludens toxin.

### Claim 16 (depends on 14)

A kit according to claim 14, wherein at least one antibody was raised against a protein comprising a fragment of zonula occludens toxin.

### Claim 17 (depends on 14)

A kit according to claim 14, wherein the first antibody was raised against a protein comprising a fragment of zonula occludens toxin.

### Claim 18 (depends on 14)

A kit according to claim 14, wherein the first antibody was raised against a protein comprising AG fragment of zonula occludens toxin.

### Claim 19 (depends on 14)

A kit according to claim 14, wherein at least one antibody was raised against a protein comprising zonula occludens toxin.

### Claim 20 (depends on 14)

A kit according to claim 14, wherein the second antibody was raised against a protein comprising zonula occludens toxin.

### Claim 21 (depends on 14)

A kit according to claim 14, wherein the second antibody comprises a detectable moiety.

### Claim 22 (depends on 21)

A kit according to claim 21, wherein the detectable moiety comprises biotin.

### Claim 23 (depends on 13)

A kit according to claim 13, further comprising a container selected from the group consisting of a container containing zonulin, a container contain the AG fragment of ZOT, a container containing TARC, a container containing MDC, and a container containing IP-10.

### Claim 24 (depends on 13)

A kit according to claim 13, comprising means for detecting a chemokine selected from the group consisting of TARC, MDC, and IP-10.

### Claim 25

A method for treating asthma in a subject in need thereof, comprising:
contacting the subject with a composition comprising a tight junction antagonist.

### Claim 26 (depends on 25)

A method according to claim 25, wherein the antagonist comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24.

### Claim 27 (depends on 25)

A method according to claim 25, wherein the antagonist comprises SEQ ID NO:15.

### Claim 28 (depends on 25)

A method according to claim 25, wherein the composition comprises a therapeutic agent.

### Claim 29 (depends on 28)

A method according to claim 28, wherein the therapeutic agent is selected from a group consisting of muscle relaxers, bronchodilators and anti-inflamatories.

### Claim 30 (depends on 28)

A method according to claim according to claim 28, wherein the therapeutic agent is selected from the group consisting of β-2-agonists, albuterol, metaproterenol sulfate, Combivent, Duoneb, Maxair, Tornalate, Ventolin, Xoponex, anticholinergics, ipratropium, cromolyn, nedocromil, beclomethasone, budesonide, fluticasone, mometasone, corticosteroids, salmeterol, formoterol, Advair, Serevent, and Foradil.

### Claim 31

A method of monitoring the treatment of asthma in a subject, comprising:
obtaining a first sample from the subject; and
determining zonulin level in the first sample;
obtaining a second sample;
determining zonulin level in the second sample,
wherein a difference in zonulin level between the first sample and the second sample is indicative of a change in severity of asthma in the subject.

### Claim 32 (depends on 31)

A method according to claim 31, wherein the zonulin level in the second sample is lower than the zonulin level in the first sample and the change in level indicates a reduction in severity.

### Claim 33 (depends on 31)

A method according to claim 31, wherein the zonulin level in the second sample is higher than the zonulin level in the first sample and the change in level indicates an increase in severity.

### Claim 34 (depends on 31)

A method according to claim 31, wherein the samples are bronchoalveolar lavage (BAL) samples.

### Claim 35 (depends on 31)

A method according to claim 31, wherein the samples are serum samples.

### Claim 36 (depends on 31)

A method according to claim 31, further comprising determining one or more chemokines in the samples.

### Claim 37 (depends on 36)

A method according to claim 36, wherein at least one of the chemokines is selected from the group consisting of TARC, MDC, and IP-10.
